NELFINAVIR
- Product Name
- NELFINAVIR
- CAS No.
- 159989-64-7
- Chemical Name
- NELFINAVIR
- Synonyms
- AG 1341;nefinavir;NELFINAVIR;NELFINAVIR-12;Nelfinavir D5;8a-beta))-a-bet;NELFINAVIR iMpurity;NELFINAVIR USP/EP/BP;Nelfinavir (AG-1341);Nelfinavir Regeoisomer
- CBNumber
- CB8213806
- Molecular Formula
- C32H45N3O4S
- Formula Weight
- 567.78
- MOL File
- 159989-64-7.mol
NELFINAVIR Property
- Melting point:
- 185-186 °C
- Boiling point:
- 786.8±60.0 °C(Predicted)
- alpha
- D -119.23° (c = 0.26 in methanol)
- Density
- 1.22±0.1 g/cm3(Predicted)
- storage temp.
- under inert gas (nitrogen or Argon) at 2–8 °C
- solubility
- ≥ 20.45mg/mL in Ethanol
- form
- Powder
- pka
- pKa1 6.0; pKa2 11.06(at 25℃)
- color
- White to off-white
- Water Solubility
- 7g/L(temperature not stated)
Safety
- Toxicity
- rat,LD,oral,> 5gm/kg (5000mg/kg),Toxicologist. Vol. 42, Pg. 55, 1998.
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
- Precautionary statements
-
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- B1122
- Product name
- Nelfinavir
- Packaging
- 5mg
- Price
- $50
- Updated
- 2021/12/16
- Product number
- CS-0677
- Product name
- Nelfinavir
- Purity
- 96.90%
- Packaging
- 5mg
- Price
- $100
- Updated
- 2021/12/16
- Product number
- E178
- Product name
- Nelfinavir
- Packaging
- 2mg
- Price
- $139
- Updated
- 2021/12/16
- Product number
- CS-0677
- Product name
- Nelfinavir
- Purity
- 96.90%
- Packaging
- 10mg
- Price
- $140
- Updated
- 2021/12/16
- Product number
- CS-0677
- Product name
- Nelfinavir
- Purity
- 96.90%
- Packaging
- 50mg
- Price
- $280
- Updated
- 2021/12/16
NELFINAVIR Chemical Properties,Usage,Production
Uses
Antiviral.
Definition
ChEBI: An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.
Indications
Nelfinavir (Viracept) is probably the most commonly used protease inhibitor because of its low incidence of serious adverse effects. Its most common side effects are diarrhea and flatulence; these may resolve with continued use. In addition to the drugs contraindicated for use with all protease inhibitors, amiodarone, rifampin, and quinidine are contraindicated in patients taking nelfinavir.
brand name
Viracept (Agouron).
Antimicrobial activity
Nelfinavir inhibits HIV-1 and HIV-2 proteases. Bioavailability is affected to only a limited degree by combination with lowdose ritonavir.
Acquired resistance
Resistance is most frequently selected through a D30N mutation in the HIV protease. An L90M mutation also confers resistance.
Pharmaceutical Applications
A synthetic chemical formulated as the mesylate for oral administration.
Pharmacokinetics
Oral absorption: c. 70–80% (with food)
Cmax 750 mg thrice daily: c. 3–4 mg/L
1250 mg twice daily: c. 4 mg/L
Cmin 750 mg thrice daily: c. 1–3 mg/L
1250 mg twice daily: c. 0.7–2.2 mg/L
Plasma half-life: c. 3.5 h
Volume of distribution: c. 2–7 L/kg
Plasma protein binding: >98%
Absorption and distribution
Food improves the bioavailability and the drug should be administered with a light meal. The semen:plasma ratio is 0.07. It is distributed into breast milk.
Metabolism and excretion
One major and several minor oxidative metabolites are found in plasma. Most of an oral dose is recovered in feces as unchanged drug (22%) and metabolites (78%). The remainder is recovered in urine, mainly unchanged.
An increase in the area under the time–concentration curve (AUC) has been observed in patients with hepatic impairment, but specific dose recommendations have not been made.
Clinical Use
Treatment of HIV infection (in combination with other antiretroviral drugs)
Side effects
The most common adverse effect is diarrhea of mild to moderate severity. Other side effects include nausea, fatigue, vomiting and headache. It is associated with less dyslipidemia in comparison with ritonavir-boosted protease inhibitors.
Metabolism
Following oral administration, nelfinavir peak levels in plasma ranged from 0.34 mg/mL (10 mg/kg in the dog) to 1.7 mg/mL (50 mg/kg in the rat). In the dog, nelfinavir was slowly absorbed, and bioavailability was 47%. The drug appeared to be metabolized in the liver, and the major excretory route was in feces.
NELFINAVIR Preparation Products And Raw materials
Raw materials
Preparation Products
NELFINAVIR Suppliers
- Tel
- --
- Fax
- --
- sales@chemos-group.com
- Country
- Germany
- ProdList
- 6350
- Advantage
- 71
View Lastest Price from NELFINAVIR manufacturers
- Product
- NELFINAVIR 159989-64-7
- Price
- US $1.10/g
- Min. Order
- 1g
- Purity
- 99.9%
- Supply Ability
- 100 Tons Min
- Release date
- 2021-07-15
- Product
- Nelfinavir 159989-64-7
- Price
- US $15.00-10.00/KG
- Min. Order
- 1KG
- Purity
- 99%+ HPLC
- Supply Ability
- Monthly supply of 1 ton
- Release date
- 2021-07-10
- Product
- Nelfinavir 159989-64-7
- Price
- US $15.00-10.00/KG
- Min. Order
- 1KG
- Purity
- 99%+ HPLC
- Supply Ability
- Monthly supply of 1 ton
- Release date
- 2021-07-09